Zoledronic acid delays disease progression of bone metastases from hepatocellular carcinoma

Yoshio Katamura(Hiroshima University), Kazuaki Chayama(RIKEN Center for Integrative Medical Sciences), Akira Hiramatsu(Hiroshima University), Masahiro Kenjo(Hiroshima University), Tomokazu Kawaoka(Hiroshima University), Hiroshi Aikata(Hiroshima Prefectural Hospital), Shoichi Takahashi(Hiroshima University), Yoshimasa Hashimoto(Frontier Science Foundation), Shintaro Takaki(Frontier Science Foundation), Yuki Kimura(Jichi Medical University), Yoshiiku Kawakami(Hiroshima University Hospital), Koji Waki(Frontier Science Foundation)
Hepatology Research
October 7, 2010
10.1111/j.1872-034x.2010.00729.x
Cited by 25

Related Papers

A proposed system for the nomenclature of hepatitis C viral genotypes
|Hepatology|1994|1k
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
|Gut|2019|732
Endothelial Cells Are Essential for the Self-Renewal and Repopulation of Notch-Dependent Hematopoietic Stem Cells
|Cell stem cell|2010|670
Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases
|Nature Genetics|2020|599
T Cell-Specific Loss of Pten Leads to Defects in Central and Peripheral Tolerance
|Immunity|2001|594